Harrow Health, Inc. (HROW) Stock Score, Valuation & Financial Research
Harrow Health, Inc. is in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 24/100.
Quick answer for HROW
Harrow Health, Inc. currently has a Wall Street Score of 24/100. The stored market price is $34.48. Its financial score is 17/100. Its valuation score is 0/100. The latest WSS change is +0.2 points. These figures are a research snapshot, not a buy or sell recommendation.
What Harrow Health, Inc. does
Harrow Health, Inc. operates as a healthcare enterprise with a specialized focus on ophthalmic solutions. The company's portfolio includes ImprimisRx, a business dedicated to ophthalmology outsourcing and pharmaceutical compounding, as well as DEXYCU, a product utilized for managing post-operative inflammation. Beyond its direct offerings, Harrow Health maintains equity investments in several pharmaceutical ventures. These encompass Surface Ophthalmics, Inc., a clinical-stage firm actively developing and commercializing therapeutic agents for ocular surface diseases; Melt Pharmaceuticals, Inc., another clinical-stage entity concentrating on proprietary non-intravenous sedation and anesthesia treatments for various medical procedures conducted in hospital, outpatient, and office environments; and Eton Pharmaceuticals, Inc., a commercial-stage company involved in the creation and market la
HROW financial snapshot
- Wall Street Score:
- 24/100
- Current price:
- $34.48
- Market capitalization:
- $1.29B
- Revenue:
- $275.6M
- Net income:
- $-37.2M
- Free cash flow:
- $42.8M
- Cash:
- $83.9M
- Total debt:
- $300.7M
- EPS:
- -0.14
- Financial score:
- 17/100
- Valuation score:
- 0/100
- Revenue score:
- 23/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $42.8M, showing positive cash generation.
- The balance sheet shows $83.9M of cash versus $300.7M of total debt, so leverage deserves attention.
- The latest Wall Street Score change is +0.2 points: HROW increased 0.2 points because overall fundamentals improved.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 17/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-08-14.
How to research HROW
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.